Monica Bertagnolli, MD, FACS, FASCO
Monica Bertagnolli, MD, FACS, FASCO, was recently elected to the Prevent Cancer Foundation’s Board of Directors.Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology at Harvard Medical School and a member of the Gastrointestinal Cancer and Sarcoma Disease Centers at Dana-Farber/Brigham & Women’s Cancer Center, where she collaborates with colleagues in medical oncology, radiation oncology, and pathology to treat patients with cancer in a tertiary-care setting.
Dr. Bertagnolli has a background in laboratory work, focusing upon understanding the role of the inflammatory response in epithelial tumor formation. She previously led gastrointestinal correlative science initiatives within the Cancer Cooperative Groups funded by the National Cancer Institute (NCI), and she served as Chief of the Division of Surgical Oncology at Dana-Farber/Brigham & Women’s Cancer Center.
Dr. Bertagnolli has held numerous leadership roles in multi-institutional cancer clinical research consortia. She currently serves as Group Chair of the Alliance for Clinical Trials in Oncology, a nationwide NCI-funded clinical trials group. She is also Chief Executive Officer of Alliance Foundation Trials, a not-for-profit corporation that conducts international cancer clinical trials. Dr. Bertagnolli has been an active ASCO member since 1995 and served as ASCO President from 2018 to 2019.
William Magner
Shabnam Kazmi
The Prevent Cancer Foundation also recently announced that two current board members have transitioned to new roles: William Magner has been elected Board Chairman and Shabnam Kazmi has been elected Board Secretary.
